Molecular therapy. Methods & clinical development

Improving Gene Editing in Blood Stem Cells with DNA Barcoding

Updated

Abstract

A barcoded AAV6 donor template (BC-AAV) was developed to monitor edited hematopoietic stem and progenitor cells (HSPCs) following transplantation.

  • Edited HSPCs transplanted into immunodeficient mice showed hematopoiesis driven by a limited number of dominant clones despite initial barcode diversity.
  • The engraftment pattern of gene-edited cells suggested that editing does not alter clonal dynamics in this model.
  • Key improvements, including GMP-grade StemSpan AOF medium and StemRegenin-1, increased clonal diversity while preserving hematopoietic potential.
  • The NHEJ inhibitor AZD-7648 significantly enhanced editing efficiency.
  • A shorter transduction period improved engraftment and clonal balance without compromising editing outcomes.

Simplified

Funding

Competing interests

J.-C.S. is a consultant in Rocket Pharmaceuticals and is co-founder and holds equity in DanausGT Biotechnology. M.P. is on the Scientific Advisory Board of Allogene Therapeutics, holds equity in CRISPR Therapeutics, and is a founder and holds equity in Kamau Therapeutics—none of these entities were involved in these studies nor have any rights, options, nor rights to the work described. L-J.S., J.B. are employees at DanausGT Biotechnology. C.T. and V.L. were employed by Viralgen SL when the present research was conducted. The IT code used in this work is under intellectual property.
PubMed

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free